Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Accenture
US Department of Justice
Medtronic
AstraZeneca
Baxter
Cantor Fitzgerald
Boehringer Ingelheim
McKesson

Generated: April 20, 2018

DrugPatentWatch Database Preview

ORTHO EVRA Drug Profile

« Back to Dashboard

When do Ortho Evra patents expire, and what generic alternatives are available?

Ortho Evra is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in ORTHO EVRA is ethinyl estradiol; norelgestromin. There are twenty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ethinyl estradiol; norelgestromin profile page.
Drug patent expirations by year for ORTHO EVRA
Synonyms for ORTHO EVRA
17-Deacetylnorgestimate
17-Desacetyl Norgestimate
3046AH
53016-31-2
AKOS015917579
BDBM50103633
BRN 4202099
CAS-53016-31-2
CHEBI:135398
CHEMBL1200807
D05205
DSSTox_CID_26788
DSSTox_GSID_46788
DSSTox_RID_81906
DTXSID9046788
Evra
HY-G0018
I14-9730
MolPort-044-724-624
NCGC00168787-01
Norelgestromin
Norelgestromin (USAN/INN)
Norgestimate metabolite Norelgestromin
progestin norelgestromin
RWJ-10553
SCHEMBL3163347
Tox21_112647

US Patents and Regulatory Information for ORTHO EVRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms ORTHO EVRA ethinyl estradiol; norelgestromin FILM, EXTENDED RELEASE;TRANSDERMAL 021180-001 Nov 20, 2001 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ORTHO EVRA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms ORTHO EVRA ethinyl estradiol; norelgestromin FILM, EXTENDED RELEASE;TRANSDERMAL 021180-001 Nov 20, 2001 ➤ Sign Up ➤ Sign Up
Janssen Pharms ORTHO EVRA ethinyl estradiol; norelgestromin FILM, EXTENDED RELEASE;TRANSDERMAL 021180-001 Nov 20, 2001 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ORTHO EVRA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Transdermal System 0.15 mg/0.02 mg per 24 hours ➤ Subscribe 2007-03-22

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
McKesson
Argus Health
US Army
Deloitte
Johnson and Johnson
Chubb
Baxter
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.